Welcome | Regenerative Medicine Investors

The Scorecard is a performance management tool which can be used by investors to keep track of the execution of activities and to monitor the consequences arising from these actions.

The characteristic of the Scorecard and its content is the presentation of a mixture of financial and non-financial measurements that should be compared to a 'target' value. The Scorecard is not meant to be a replacement for traditional financial or operational reports but a series of spreadsheets that captures succinct data and information relevant to those making investment decisions. The scorecard also gives light to the RegMed sector or company's not always considered metrics.

As a model of performance, the Scorecard is effective in that "it articulates the links between leading inputs, outcomes and focuses on the importance of those management processes to achieve a matrix for investors to measure performance versus priorities.

Submitted by Henry McCusker on December 10, 2013 - 12:47pm

“Cash is king" is an acute expression used in analyzing the RegMed universe to the importance of operating funds available in the development and trial process and the overall fiscal health of a business.

For investors it may also describe times when it is advantageous to understand capital market access and the resulting dilution and the availability of an investment opportunity.

COMPANY	SYMBOL	CASH (in millions)	Q4/13 OP. EXP. (in millions)	FY13 OP. EXP. (in millions)
Mesoblast	MBLTY	$259.93 (Yahoo)	NA	NA
bluebird	BLUE	$206.3	$14.50	$45.10
Stemline	STML	NA	NA	NA
Dendreon	DNDN	$199.40	$117.80	$360.30
Cellular Dynamics	ICEL	$62.00	$9.70	$25.60
Fibrocell	FCSC	$60.33	$4.20	$22.70
MiMedx	MDXG	$56.90	$3.60	$9.90
NeoStem	NBS	$46.10	$11.20	$38.50
Athersys	ATHX	$31.90	$7.49	$26.84
Stemcells	STEM	$30.60	$9.70	$29.50
Immunocellular	IMUC	$27.60	$2.50	$9.40
Opexa	OPXA	$23.60	$4.77	$13.24
Verastem	VSTM	$19.00	$11.40	$41.40
Neuralstem	CUR	$16.80	$3.23	$12.55
Organovo	ONVO	$16.80	$5.60	NA
Cytori	CYTX	$15.50	$11.45	$39.44
Northwest Bio	NWBO	NA	NA	NA
Tengion	TNGN	NA	NA	NA
Harvard Apparatus	HART	NA	NA	NA
Aastrom	ASTM	$8.10	$4.90	$21.00
BioTime	BTX	$5.50	$31.00	$59.70
Pluristem	PSTI	$5.00	$5.00	$15.40
Bioheart	BHRT	NA	NA	NA
Advanced Cell	ACTC	NA	NA	NA
Cesco Therapeutics	KOOL	$2.33	$3.40	$11.60
Cytomedix	CMXI	NA	NA	NA
Capricor	CAPR	NA	NA	NA
Int'l Stem Cell	ISCO	$2.3	$3.13	$12.10
Osiris	OSIR	NA	NA	NA
BioRestorative	BRTX	NA	NA	NA
Medistem	MEDS	NA	NA	NA
Brainstorm	BCLI	NA	NA	NA
BioLife Solutions	BLFS	$0.17	$1.20	$4.00
VistaGen	VSTA	$0.02	$1.44	$7.00

Submitted by Henry McCusker on May 17, 2014 - 1:31pm

An earnings release is a ‘scorecard’ of sorts for a public regenerative medicine company.

The current LPS (loss per share) standings reflect the universes’ investing status; then add in their cash position for a better snapshot! By analyzing these comparisons, investors can begin to gauge the financial health versus the scientific opportunity of regenerative medicine research and whether or not it deserves their investment.

COMPANY	SYMBOL	Q1-14 LOSS	Q1-14 LPS	Q1/14 CASH
Aastrom	ASTM	-$6.0 M	-$1.26	$8.8 M
Advanced Cell	ACTC	-$8.7 M	$0.00	$45.0 M
Athersys	ATHX	-$11.5 M	-$0.15	$45.0 M
AxoGen	AXGN	-$4.2 M	-$0.24	$16.8 M
Bioheart	BHRT	+$677.4 K	+$0.001 diluted	$219.0 K
BioLife Solutions	BLFS	-$-559.3 K	-$0.10	$12.8 M
BioRestorative	BRTX
BioTime	BTX
bluebird	BLUE	-10.6 M	-$0.44	$192.5 M
Brainstorm	BCLI
Capricor	CAPR	-$1.2 M	-$0.10	$13.0 M
Cellular Dynamics	ICEL	-$5.7 M	-$3.28	$53.7 M
Cesca	KOOL	-$1.9 M	-$0.07	$6.6 M
Cytomedix	CMXI
Cytori	CYTX	-$10.4 M	-$0.14	$12.8 M
Dendreon	DNDN	-$36.4 M	-$0.24	$90.1 M
Fate	FATE	-$7.0 M	-$0.34	$47.8 M
Fibrocell	FCSC	-$14.0 M	-$0.35	$54.0 M
Harvard Apparatus	HART	-$3.0 M	-$0.39	$12.6 M
ImmunoCellular	IMUC	$-3.2 M	-$0.05	$25.0 M
Int'l. Stem Cell	ISCO	-$1.4 M	-$0.01	$991 K
Mesoblast	MBLTY
MiMedx	MDXG	-$922.1 M	-$0.01	$43.0 M
NeoStem	NBS	-$13.7 M	-$0.49	$41.4 M
Northwest Bio	NWBO
Organovo	ONVO
OPXA	OPXA	-$3.7 M	-$0.13	$19.7 M
Osiris	OSIR	-$1.36 M	-$0.04	$2.34 M
Pluristem	PSTI	-$20.7 M	-$0.14	$3.6 M
StemCells	STEM	-$7.6 M	-$0.14	$26.5 M
Stemline	STML
Tengion	TNGN	-$34.2 M	-$2.11	$15.4 M
Verastem	VSTM	-$13.0 M	-$0.51	$13.2 M
VistaGen	VSTA

Submitted by Henry McCusker on May 17, 2014 - 1:27pm

An earnings release is a ‘scorecard’ of sorts for a public regenerative medicine company.

COMPANY	SYMBOL	Q1 LOSS/LPS	Q1 CASH	Q2 LOSS/LPS	Q2 CASH	Q3 LOSS/LPS	Q3 CASH	Q4 LOSS/LPS	Q4 CASH
Aastrom	ASTM	-$7.2 M/-$3.00	$9.2 M	-$5.2 M/-$2.20	$4.5 M	-$3.6 M/-$0.06	$10.8 M	-2.9 M/-$0.97	$8.0 M
Advanced Cell	ACTC	-$6.4 M/$0.00	$4.1 M	-$6.6 M/$0.00	$5.5 M	-$6.3 M/$0.00	$5.5 M	-$12.8 M/$0.00	$1.7 M
Athersys	ATHX	-$9.3 M/-$0.18	$21.3 M	-$5.9 M/-$0.1	$18.9 M	-$5.6 M/-$0.1	$17.8 M	-$9.8 M/-$0.15	$32.0 M
AxoGen	AXGN	-$3.5 M/ -$.022	$22.4 M	-$3.6 M/-$0.22	$8.7 M	-$4.1 M/-$0.31	$22.6 M	-$4.2 M/-$0.31	$20.0 M
Bioheart	BHRT	-$519 K/$0.00	$239.0 K	-$750 K/-$0.01	$173 K	-$1.1 M/$0.00	$7.0 K	/-$727 K$0.00	$46.0 K
BioLife Solutions	BLFS	-$297.0 K/$0.00	$61.5 K	-$283 K/$0.00	$76.0 K	-$310 K/-$0.14	$79.0 K	-485.0 K/-$0.08	$156.0 K
BioRestorative	BRTX	-$1.6 M/-$0.01	$498.6 K	-$1.3 M/-$0.08	$0.00	-$1.3 M/-$0.07	$1.0 K	-$1.6 M/-$0.01	$201.0 K
BioTime	BTX	-$7.7 M/-$0.15	$9.9 M	-$19.6 M/-$0.14	$14.3 M	-9.0 M/-$0.16	$6.7 M	-$19.6 M/-$0.36	$5.5 M
bluebird	BLUE	-$6.5 M/-$19.94	NA	-$4.6 M/$11.00	$22.8 M	-$6.1 M/$6.98	$216.7 M	-$8.1 M/-$0.06	$206.0 M
Brainstorm	BCLI	-$1.1 M/-$0.05	$1.9 M	-$1.5 M/$0.04	$755.0 K	-$1.1 M/-$0.01	$429.0 K	-$1.2 M/-$0.01	$3.5 M
Capricor	CAPR	-483 K/-$0.50	$285.0 K	-$598 K/-$1.00	$$229.0 K	-$348 K/-0.00	$71.0 K	-$7.46 M/-$0.65	$3.1 M
Cellular Dynamics	ICEL	NA/-$3.28	NA	-$-5.0 M/-$2.92	$33.5 M	-$7.5 M/-$2.71	$68.6 M	-$6.7 M/-$0.32	$62.0 M
Cesca*	KOOL	-$1.1 M/-$0.06	$7.5 M	-$2.4 M/-$0.03	$6.9 M	-$2.3 M/-$0.07	$5.3 M	-$1.6 M/-$0.15	$2.3 M
Cytomedix	CMXI	$7.8 M/-$0.11	$7.2 M	-$3.2 M/-$0.05	$13.6 M	-$5.3 M/-$0.08	$10.2 M	-$10.0 M/$0.15	$15.5 M
Cytori	CYTX	-$7.8 M/-$.011	$16.4 M	-$3.2 M/-$0.05	$13.6 M	-$5.3 M/-$0.08	$10.2 M	-$10.0 M/-$0.15	$15.5 M
Dendreon	DNDN	-$72.0 M/-$0.48	$130.5 M	-$69.0 M/-$0.58	$92.0 M	-$67.2 M-$0.44	$87.7 M	-$88.7 M/-$0.58	$92.5 M
Fate	FATE	NA	NA	NA	NA	-$5.7 M/-$4.83	$19.0 M	-$6.0 M/+$8.70	$54.0 M
Fibrocell	FCSC	-$5.8 M/-$0.22	$26.1 M	-$12.9 M/-$0.24	$26.1 M	-$6.2 M/-$0.48	$20.8 M	-$5.8 M/-$0.09	$16.9 M
Harvard Apparatus	HART	NA	NA	NA	NA	NA	NA	-$2.6 M/-$0.34	$14.0 M
ImmunoCellular	IMUC	-$5.0 M/-$0.01	$24.1 M	-$150 K/$0.00	$25.4 M	-$3.8 M/-$0.07	$29.4 M	$-117 K/-$0.01	$27.6 M
Int'l. Stem Cell	ISCO	-$1.7 M/-$0.02	$1.9 M	$-2.2 M/-$0.02	$704.0 K	-$3.8 M/-$0.03	$1.8 M	-$-2.8 M/-$0.02	$2.3 M
Mesoblast	MBLTY	NA	NA	NA	NA	NA	NA	NA	NA
MiMedx	MDXG	$1.6 M/-$0.02	$5.7 M	-$757 K/-$0.01	$4.2 M	-$307 K/$0.00	$6.0 M	-$1.4 M/-$0.01	$44.1 M
NeoStem	NBS	-$8.8 M/-$0.53	$9.3 M	-$8.6 M/-$0.46	$14.7 M	-$9.1 M/-$0.45	$16.9 M	-$12.4M/-$0.47	$46.1 M
Northwest Bio	NWBO	-$/14.4 M/-$0.54	$373.0 K	-$11.6 M/-$0.40	$2.0 M	-$22.9 M/-$0.65	$7.4 M	-$16.89 M/-$2.00	$18.5 M
Organovo	ONVO	NA	$15.6 M	-$3.8 M/-$0.06	$12.8 M	-$10.4 M/-$0.14	$53.3 M	-$5.2 M/-$0.07	$49.8 M
OPXA	OPXA	-$4.2 M/-$0.58	$7.8 M	-$3.0 M/-$0.37	$5.0 M	-$346.2 K/-$0.39	$20.2 M	-$3.8 K/+0.04	$23.6 M
Osiris	OSIR	-$2,8 M/-$0.08	$1.3 M	-$3.8 M/-$0.11	$1.6 M	-$1.6 M/-$0.05	$1.8 M	+49.8 M/+$1.44	$2.4 M
Pluristem*	PSTI	-$5.7 M/-$0.08	$28.8 M	-$6.7 M/-$0.08	$9.3 M	-$4.8 M/-$0.01	$9.4 M	-$7.0 M/-$0.12	$5.1 M
StemCells	STEM	-$6.4 M/-$0.17	$7.2 M	-$5.9 M/-$0.18	$22.6 M	-$7.2 M/-$0.17	$21.0 M	-7.6 M/-$0.14	$30.6 M
Stemline	STML	-$5.5M/-$0.09	$30.7 M	-$5.5 M/-$0.47	$92.7 M	-$5.6 M /-$0.37	$87.7 M	-$7.7 M/-$0.61	$44.2 M
Tengion	TNGN	-$ 5.8 M/-$2.11	$7.5 M	-$ 11.9 M/-$3.73	$13.9 M	-$ 7.3 M/-$1.40	$22.5 M	+$6.0 M/$2.54	$21.5 M
Verastem	VSTM	-$9.0 M /-$0.44	$28.2 M	-$10.2 M/ -$0.50	$13.9 M	-$10.6 M /-$0.43	$22.6 M	-$11.3 M/-$0.45	$19.0 M
VistaGen*	VSTA	$131 K /-$0.16	$638 K	-$1.5 M /-$0.02	$90.0 K	+$186 K /-$0.04	$7.0 K	-$3.7 M/-$0.02	$21.0 K

* Jul - Jun Rptg.

Submitted by Henry McCusker on November 16, 2013 - 7:45pm

COMPANY	SYMBOL	REVENUE	DEBT	CASH	RECENT FINANCING	OP. EXP. Q1/14	FINANCE NEEDED?
Advanced Cell	ACTC	$39.5 K	$1.09 M	4.0 M		$7.7 M	Yes
Aastrom	ASTM	$11.00 K	$2.00 K	$8.84 M	$15 M (1/14)	$4.65 M	Yes
Athersys	ATHX	$707.0 K	$178.00 K	$44.98 M	$5 M (1/14)	$8.09 M
AxoGen	AXGN	$3.1 M	$26.26 M	$16.81 M		$5.42 M
Brainstrom	BCLI	NA	$0.00	$3.03 M	$3.7M (8/13)	$1.03 M	Yes
Bioheart	BHRT	$322.5 K	$5.65 M	$218.98 K		$943.5 K
Biolife Solutions	BLFS	$2.0 M	$0.00	$12.84 M	$15.4 (3/14)	$1.27 M
bluebird	BLUE	$6.3 M	$0.00	$192.5 M		$17.0 M
BioRestorative	BRTX	$375.00	$5.46 M	$110.36 K	$375.00 K (6/14)	$1.4 M	YES
BioTime	BTX	$1.0 M	$0.00	$6.64 M	$3.5 M (3/14)	$12.0 M	YES
Cytomedix	CMXI	$1.85 M	$2.18 M	$7.65 M	$35 M Debt Facility (4/14)	$5.0 M	YES
Neuralstem	NYSEMKT: CUR	$4.16 K	$7.04 M	$33.34 M	$19.65 M (1/14)	$5.18 M	Filed New Shelf
Cytori	CYTX	$1.0 M	$26.57 M	$12.80 M	$10.0 M (5/14)	$10.56 M	Yes
Dendreon	DNDN	$68.7 M	$609.58 M	$155.15 M		$91.86 M
Fibrocell	FCSC	$46 K	$0.00	$54.00 M	$11M (9/13)	$11.2 M
Harvard Apparatus	HART	$20.3 K	$0.00 M	$12.61 M		$3.0 M	Yes
Cellular Dynamics	ICEL	$2.39 M	$11.91 M	$53.7 M	$46 M (7/13)	$8.07 M
Immunocellular	IMUC	$1.65 M	$0.00	$25.45 M		$3.71M
Int'l Stem Cell	ISCO	$5.18 M	$0.00	$991.00 K		$1.64 M
Cesca Therap.	KOOL	$4.03 M	$0.00	$6.57 M	$6.67 (1/14)	$3.39 M
Mesoblast	MBLTY	$35.37 M	$0.00	$323.16 M		NA
MiMedx	MDXG	$43.53 M	$0.00	$43.0 M	$34 M (12/13)	$18.0 M
NeoStem	NBS	$4.0 M	$4.89 M	$41.36 M	$32.55 M (10/13)	$17.55 M
Northwest Bio	NWBO	$0.0	$1.17 M	$12.23 M	$32 M RDO $15 M initial sale	$23.68 M
Organovo	ONVO	$135.0 K	$18.0 K	$49.81 M	$46.6 M (8/13)	$4.7 M
Opexa	OPXA	$348.83 K	$0.00	$10.66 M	$8.054 M (12/13)	$3.66 M
Osiris	OSIR	$10.05 M	$45.00 K	$38.96 M		$8.45 M
Proteonomix	PROT	$26.00 K	$2.71 M	$2.40 M		$849.00 K / $2.21 M	Yes
Pluristem	PSTI	$285 K	$0.00	$60.12 M		$7.30 M/ $6.12 M
StemCells	STEM	$339.48 K	$15.96 M	$26.46 M	$18.6 M (10/13) $3.8 M (7/13)	$7.15 M
Stemline	STML	$71.00 K	$0.00	$24.20 M		$9.10 M
Tengion	TNGN	$0.00	$29.01 M	$15.37 M	$18.6 M (7/13)	$4.14 M	Yes
VistaGen	VSTA	$0.00 K	$6.39 M	$20.7 K		$1.44 M
Verastem	VSTM	$0.00	$0.00	$13.24 M	$50 M (7/13)	$13.13 M

Submitted by Henry McCusker on November 16, 2013 - 6:39pm

COMPANY	SYMBOL	TRIAL	FOCUS
Advanced Cell	(ACTC)	RPE	Macular Degenration
Advanced Cell	(ACTC)	RPE	Dry Age-Related Macular Degeneration
Advanced Cell	(ACTC)	RPE	Stargardt's Macular Dystrophy (SMD)

COMPANY	SYMBOL	TRIAL	FOCUS	PHASE
Advanced Cell	(ACTC)	RPE	Macular Degenration	P2
Advanced Cell	(ACTC)	RPE	Dry Age-Related Macular Degeneration	P2
Advanced Cell	(ACTC)	RPE	Stargardt's Macular Dystrophy (SMD)	P2
Aastrom	(ASTM)	ixCELL-DCM	Ischemic Dilated Cardiomyopathy	P2b
Athersys	(ATHX)	MultiStem®	Inflammatory Bowel Disease	P2
Athersys	(ATHX)	MultiStem®	HSC Transplant/GVHD	Orphan Status Granted
Athersys	(ATHX)	MultiStem®	Solid Organ Transplant	Trial authorized in Germany
Athersys	(ATHX)	MultiStem®	Diabetes	Preclinical
Athersys	(ATHX)	MultiStem®	Acute Myocardial Infarction	P2
Athersys	(ATHX)	MultiStem®	PVD/PAD/CLI	Preclinical
Athersys	(ATHX)	MultiStem®	Congestive Heart Failure	Preclinical
Athersys	(ATHX)	MultiStem®	Ischemic Stroke	P2
Athersys	(ATHX)	MultiStem®	Traumatic Brain Injury	Preclinical
Athersys	(ATHX)	MultiStem®	Multiple Sclerosis	Preclinical
Athersys	(ATHX)	MultiStem®	Spinal Cord Injury	Preclinical
Bioheart	(ZOTC: BHRT)	ANGEL	Agiogenesis (Blood Cells/Healing)	P1
Bioheart	(BHRT)	MARVEL	Cardiac Disease/MI	P2/3
Bioheart	(BHRT)	MIRROR	Cardiac Disease/MI	P3
Bioheart	(BHRT)	MYOHEART	Cardiac Disease/MI	P1
Bioheart	(BHRT)	REGEN	Cardiac Disease/MI	P1
Bioheart	(BHRT)	Drug: MyoCell	Congestive Heart Failure	P2
Bioheart	(BHRT)	Procedure: Hypothermosol	Congestive Heart Failure	P3
Biorestorative	(BRTX)	NA	NA	NA
BioLife Solutions	(BLFS)	NA	Tools company supplying	NA
Dendreon	(DNDN)	Active Cellular Immunotherapy	Ovarian Cancer Expressing HER2/NEU	P1
Dendreon	(DNDN)	Active Cellular Immunotherapy	Colorectal Cancer Expressing HER2/NEU	P1
FibroCell	(NTSE MKT: FCSC)	Isolagen Therapy™	Nasolabial Fold Wrikles	P3 Completed.
FibroCell	(FCSC)	Isolagen Therapy™	Acne Scarring w/Therapy	P2
FibroCell	(FCSC)	Isolagen Therapy™	Acne Scarring w/Placebo	P3 Completed.
FibroCell	(FCSC)	Isolagen Therapy™	Restrictive Burn Scars	P2
FibroCell	(FCSC)	Isolagen Therapy™	Interdental Papillary Insufficiency	P2
International Stem	(OTC: ISCO)	Dopaminergic Neurons	Parkinson's Disease	Preclinical
International Stem	(OTC: ISCO)	Hepatocytes	Liver Disease	Preclinical
International Stem	(OTC: ISCO)	Corneal Tissue	Blindness	Preclinical
Harvard Appartus	(HART)
Immunocellular	(IMUC)	ICT-121	Recurrent Glioblastoma	P1
Immunocellular	(IMUC)	ICT-107	Vaccine for Glioblatoma	P2
Immunocellular	(IMUC)	ICT-140	Ovarian Cancer	Preclinical
Mesoblast ADR	(US OTC: MBLTY)	Allogenic Meneschymal	Damaged Intervertebral Discs	P2
Mesoblast	(MBLTY)	Immunologic Inflammatory	Rheumatoid Arthritis	P2
Mesoblast	(MBLTY)	Immunologic Inflammatory	Asthma Pulmonary Fibrosis	Preclinical
Mesoblast	(MBLTY)	Immunologic Inflammatory	Type 2 Diabetes	P2
Mesoblast	(MBLTY)	Immunologic Inflammatory	Diabetic Complications (Kidney)	P2
Mesoblast	(MBLTY)	Spine Disease	Spinal Fusion	P2
Mesoblast	(MBLTY)	Spine Disease	Intervertebral Disc Repair	P2
Mesoblast	(MBLTY)	Cardiovascular	Congestive Heart Failure	P2
Mesoblast	(MBLTY)	Cardiovascular	Acute Myocardial Infarction	P2
Mesoblast	(MBLTY)	Cardiovascular	Chronic Angina	Preclinical
Mesoblast	(MBLTY)	Neurologic	Parkinson's Stroke	P1
Mesoblast	(MBLTY)	Eye Disease	Wet Macular Degeneration	P2
Mesoblast	(MBLTY)	Orthopedic Disease	Bone Marrow Transplantation	P3
Mesoblast	(MBLTY)	Prochymal®	Steroid Refractory Acute GvHD	P3
Mesoblast	(MBLTY)	Prochymal®	Newly Diagnosed Acute GVHD	P3
Mesoblast	(MBLTY)	Prochymal®	Pediatric Expanded Access Program	Enrolling
Mesoblast	(MBLTY)	Prochymal®	Crohn's Disease	P3/Accepting Patients
Mesoblast	(MBLTY)	Prochymal®	Type 1 Diabetes	P2
Mesoblast	(MBLTY)	Prochymal®	Cardiac	P2
Medistem	(MEDS)	ERC-123	Critical Limb Ischemia	P1
Medistem	(MEDS)	ERC-123	Congestive Heart Failure	P2
MiMidxg	(MDXG)	Amneotic Membrane	Diabetic Foot Ulcers	Comparative Study v/SOC
NeoStem	(NBS)	AMR-001	ST Segment Elevation Myocardial Infarction	P2
Neuralstem	(CUR)	NSI-566	Cell Therapy Treatments:
Neuralstem	(CUR)	NSI-566	Amotrophic Lateral Sclerosis (ALS)	P2
Neuralstem	(CUR)	NSI-566	Ischemic Stroke	P1/P2
Neuralstem	(CUR)	NSI-566	Spinal Cord Injury	P1
Neuralstem	(CUR)	NSI-566	Multiple Sclerosis	Preclinical
Neuralstem	(CUR)	NSI-566	Optic Neuritis	Preclinical
Neuralstem	(CUR)	NSI-566	Alzheimer's Disease	Preclinical
Neuralstem	(CUR)	NSI-566	Traumatic Brain Injury	Preclinical
Neuralstem	(CUR)	NSI-566	Peripheral Nerve Injury	Preclinical
Neuralstem	(CUR)	NSI-566	Lysomal Diseases	Preclinical
Neuralstem	(CUR)	NSI-566	Huntington's Disease	Preclinical
Neuralstem	(CUR)	NSI-566	Cerebral Palsy	Preclinical
Neuralstem	(CUR)	NSI-566	Ischemic Spastic Paraplegia	Preclinical
Neuralstem	(CUR)	NS-189	Drug Therapies:
Neuralstem	(CUR)	NS-189	Major Depressive Disorder	P1b
Neuralstem	(CUR)	NS-189	Alzheimer's Disease	Preclinical
Neuralstem	(CUR)	NS-189	Diabetes Cognitive Complication	Preclinical
Neuralstem	(CUR)	NS-189	Stroke	Preclinical
Neuralstem	(CUR)	NS-189	Traumatic Brain Injury	Preclinical
Neuralstem	(CUR)	NS-189	Post-Traumatic Stress Disorder	Preclinical
Neuralstem	(CUR)	NS-189	Neurodegeneration	Preclinical
Neuralstem	(CUR)	NS-189	Anti-Aging	Preclinical
Northwest Bio	(NWBO)	DCVax®	Brain Cancers	P2
Northwest Bio	(NWBO)	DCVax®	Prostate Cancer	P3
Northwest Bio	(NWBO)	DCVax®	Lung Cancer	P1
Northwest Bio	(NWBO)	DCVax®	Ovarian Cancer	P1
Northwest Bio	(NWBO)	DCVax®	Liver Cancer	P1
Northwest Bio	(NWBO)	DCVax®	Head and Neck Cancers	P1
Northwest Bio	(NWBO)	CXCR4	Antibody Drugs	P1
Opexa	(OPXA)	Abili-T	Secondary Progressive Multiple Sclerosis	P2
Opexa	(OPXA)	Tcelna®	Secondary Progressive Multiple Sclerosis	P2b FAST TRACK
Organovo	(ONVO)	NA	3D Human Tissue for Medical Research	Preclinical
Pluristem	(PSTI)	Placental eXpanded (PLX)	Peripheral Artery Disease (PAD)	P2/3
Pluristem	(PSTI)	PLX	Skeletal Injuries	Preclinical
Pluristem	(PSTI)	PLX	Adjuvant for UCB Transplantation	Preclinical
Proteonomix	(PROT)	GSF and Mozobil	End Stage Liver Disease	Phase 1
Reneuron	(RENE.L)	PISCES	Stroke	P1
StemCells	(STEM)	HuCNS-SC®	Dry Age-Related Macular Degeneration	P1/2
StemCells	(STEM)	HuCNS-SC®	Spinal Cord Injury	P1/2
StemCells	(STEM)	HuCNS-SC®	Pelizaeus-Merzbacher Disease (PMD)	P1
Stemline	(STML)	SL-401	BPDCN	P1/2
Stemline	(STML)	SL-401	Other Rare 3R+ Cancers	P1/2
Stemline	(STML)	SL-401	Acute Myeloid Leukemia (AML)	P1/2
Stemline	(STML)	SL-401	Multiple Myeloma	P1/2
Stemline	(STML)	SL-401	High Risk MDS	P1/2
Stemline	(STML)	SL-401	Other Hematologic Cancers	P1/2
Stemline	(STML)	SL-701	Pediatric Malignant Glioma	P1/2
Stemline	(STML)	SL-701	Adult High-Grade Glioma	P1/2
Tengion	(TNGN)	Neo-Urinary Conduit™	Bladder Cancer	P1
Tengion	(TNGN)	Neo-Kidney-Augment™	Chronic Kidney Disease	P1
Thermogenesis	(KOOL)	Bone Marrow Delivery	Critical Limb Ischemia	P1b
VistaGen	(VSTA)	AV-101 IND	Neuropathic Pain	P2
Verastem	(VSTM)	Defactinib (VS-6063)	Mesothelioma	P2
Verastem	(VSTM)	VS-6063 w/Paclitaxel	Ovarian Cancer	P1/1b
Verastem	(VSTM)	VS-4718	Non Hematologic Cancers	P1 - Recruiting
Verastem	(VSTM)	VS-6063	Non Small Cell Lung Cancer/Lung Cancer	P2 - Recruiting
Verastem	(VSTM)	VS-6063	JAPANESE Subjects w/Non Hematologic	P1 - Recruiting
Verastem	(VSTM)	VS-6063	Malignancies

Submitted by Henry McCusker on February 23, 2014 - 3:20pm

COMPANY	YEAR	SALARY	BONUS	STOCK AWARDS ($)	OPTIONS ($)	NON EQUITY INCENTIVE PLAN ($)	ALL OTHER COMP	TOTAL ($)	52 WEEK RANGE	CURRENT MARKET CAP
ADVANCED CELL (ACTC) Gary Rabin CEO	2013	$551.2 K	$0.00	$0.00	$0.00	$0.00	$0.00	$551.2 K	$0.05 - $0.10	$164.8 M
	2012	$525.0 K	$0.00	$0.00	$0.00	$315 K	$0.00	$840 K
	2011	$490.0 K	$649.3 K	$2.5 M	$3.45 M	$0.00	$0.00	$7.14 M
ADVANCED CELL (ACTC) Robert Lanza CSO	2013	$485.1 K	$101.1 K	$79.7 K	$69.9 K	$0.00	$0.00	$735.7 K
	2012	$462.0 K	$0.00	$0.00	$0.00	$138.6 K	$0.00	$184.6 K
	2011	$407.5 K	$255.0 K	$1.7 M	$2.5 M	$0.00	$0.00	$4.8 M
ADVANCED CELL (ACTC) Edward Myles Interim CFO	2013	$175.2 K	$135.5 K	$0.00	$1.0 M	$0.00	$0.00	$1.4 M
AASTROM (ASTM) Dominic Colangelo CEO	2013	$358.4 K	$0.00	$0.00	$937.8 K	$89.5 K	$59.3 K	$1.4 M	$3.14 - $86.00	$24.53 M
AASTROM (ASTM) Daniel Orlando COO, Interim CEO	2013	$285.0 K	$35 K	$0.00	$0.00	$45.6 K	$45.6 K	$412.2 K
AASTROM (ASTM) Daniel Orlando COO, Interim CEO	2012	$99.9 K	$0.00	$0.00	$485.4 K	$0.00	$0.5 K	$585.8 K
AASTROM (ASTM) Ronnda Bartel CSO	2013	$260.0 K	$0.00	$0.00	$0.00	$0.00	$28.9 K	$288.9 K
	2012	$253.0 K	$0.00	$0.00	$209.1 K	$0.00	$9.6 K	$471.7 K
	2011	$243.3 K	$14.8 K	$0.00	$235.9 K	$85.1 K	$7.1 K	$586.2 K
AASTROM (ASTM) Sharon Watling V.P. Dev.	2013	$79.8 K	$0.00	$0.00	$0.00	$0.00	$185.3 K	$265.1 K
	2012	$245.0 K	NA	$0.00	$199.0 K	$0.00	$10.4 K	$454.4 K
	2011	$210.6 K	NA	$0.00	$333.1 K	$70.0 K	$9.7 K	$623.4 K
AASTROM (ASTM) Brian Gibson V.P. Fin	2013	$110.0 K	$0.00	$0.00	$0.00	$0.00	$32.4 K	$265.1 K
	2012	$165.0 K	$0.00	$0.00	$319.3 K	$0.00	$21.1 K	$505.4 K
	2011	$123.3 K	$0.00	$0.00	$105.5 K	$40.0 K	$6.4 K	$275.2 K
AASTROM (ASTM) Michael Ellison CAO	2013	$113.5 K	$0.00	$0.00	$0.00	$17.5 K	$4.8 K	$135.8 K
ATHERSYS (ATHX) Gil Van Bokkelen CEO	2013	$450.0 K	$118.0 K	$1.2 M	$264.6 K	$0.00	$12.6 K	$2.03 M	$1.08 - $4.33	$118.3 M
	2012	$430.0 K	$107.5 K	$0.00	$0.00	$0.00	$12.6 K	$550.1 K
	2011	$404.5 K	$40 K	$0.00	$0.00	$0.00	$12.6 K	$457.1 K
ATHERSYS (ATHX) Laura Campbell V.P. Fin.	2013	$239.3 K	$42.0 K	$632.0 K	$85.8 K	$0.00	$5.1 K	$1.0 M
	2012	$231.5 K	$40.5 K	$0.00	$0.00	$0.00	$5.1 K	$277.1 K
	2011	$225.3 K	$15.3 K	$0.00	$0.00	$0.00	$5.1 K	$245.7 K
ATHERSYS (ATHX) William Lehmann Pres.	2013	$371.4 K	$84.0 K	$980.9 K	$164.5 K	$0.00	$4.6 K	$1.6 M
	2012	$358.8 K	$77.0 K	$0.00	$0.00	$0.00	$4.6 K	$440.4 K
	2011	$346.7 K	$27.0 K	$0.00	$0.00	$0.00	$4.6 K	$378.3 K
ATHERSYS (ATHX) John Harrington CSO	2013	$369.4 K	$83.5 K	$975.6 K	$143.0 K	$0.00	$4.4 K	$1.6 M
	2012	$357.1 K	$77.8 K	$0.00	$0.00	$0.00	$4.3 K	$439.2 K
	2011	$346.7 K	$27.0 K	$0.00	$0.00	$0.00	$4.3 K	$378.0 K
ATHERSYS (ATHX) Robert Deans EVP	2013	$318.0 K	$65.0 K	$839.9 K	$114.4 K	$0.00	$5.6 K	$1.3 M
	2012	$307.5 K	$62.3 K	$0.00	$0.00	$0.00	$5.6 K	$375.4 K
	2011	$393.8 K	$24.3 K	$0.00	$0.00	$0.00	$5.6 K	$423.7 K
AXOGEN (AXGN) Karen Zaderej CEO	2013	$299.6 K	$14.9 K	$0.00	$0.00	$0.00	$6.1 K	$322.60	$2.42 - $5.20	$45.6 M
AXOGEN (AXGN) Karen Zaderej CEO	2012	$291.2 K	$11.6 K	$0.00	$0.00	$0.00	$0.00	$310.7 K
AXOGEN (AXGN) Gregory Freitag Former CEO	2013	$240.0 K	$11.6 K	$0.00	$0.00	$0.00	$7.6 K	$259.3 K
AXOGEN (AXGN) Gregory Freitag Former CEO	2012	$204.1 K	$8.2 K	$0.00	$0.00	$0.00	$5.6 K	$217.8 K
AXOGEN (AXGN) Shawn McCarrey SVP/SALES	2013	$161.5 K	$153.0 K	$0.00	$144.5 K	$0.00	$11.9 K	$471.1 K
AXOGEN (AXGN) Jill Schiaparelli SVP/MKTG.	2013	$220.1 K	$11.0 K	$0.00	$0.00	$0.00	$6.9 K	$238.0 K
AXOGEN (AXGN) Jill Schiaparelli SVP/MKTG.	2012	$173.7 K	$6.2 K	$0.00	$208.7 K	$0.00	$5.4 K	$394.0 K
BIOHEART (BHRT) Mike Tomas CEO	2013	$391.7 K	$375.0 K	$0.00	$170.1 K	$0.00	$0.00	$936.8 K	$0.01 - $0.08	$12.6 M
	2012	$247.5 K	$0.00	$0.00	$100.0 K	$0.00	$0.00	$347.5 K
	2011	$230.5 K	$0.00	$0.00	$40.0 K	$0.00	$0.00	$270.5 K
BIOHEART (BHRT) Kristin Comella CSO	2013	$159.1 K	$125.0 K	$0.00	$81.9 K	$0.00	$0.00	$369.1 K
	2012	$105.6 K	$0.00	$0.00	$15.0 K	$0.00	$0.00	$120.6 K
	2011	$106.2 K	$0.00	$0.00	$20.0 K	$0.00	$0.00	$126.2 K
BIOLIFE SOLUTIONS (BLFS) Michael Rice CEO	2013	$300.0 K	$150.0 K	$0.00	$0.00	$0.00	$0.00	$450.0 K	$1.85 -$23.94	$13.8 M
	2012	$285.0 K	$150.0 K	$0.00	$0.00	$0.00	$24.1 K	$459.1 K
	2011	$270.0 K	$0.00	$0.00	$161.2 K	$0.00	$0.00	$431.2 K
BIOLIFE SOLUTIONS (BLFS) Daphne Taylor CFO	2013	$194.0 K	$19.4 K	$0.00	$0.00	$0.00	$0.00	$213.8 K
	2012	$160.0 K	$18.0 K	$0.00	$19.7 K	$0.00	$0.00	$197.7 K
	2011	$102.0 K	$0.00	$0.00	$44.1 K	$0.00	$0.00	$146.2 K
BIOLIFE SOLUTIONS (BLFS) Aby Matthew CTO	2013	$218.0 K	$21.8 K	$0.00	$0.00	$0.00	$0.00	$239.8 K
BIOLIFE SOLUTIONS (BLFS) Aby Matthew CTO	2012	$177.8 K	$20.0 K	$0.00	$19.7 K	$0.00	$0.00	$217.5 K
BIORESTORATIVE (BRTX) Mark Weinreb CEO	2013	$360.0 K	$0.00	$0.00	$50.5 K	$0.00	$14.4 K	$425.0 K	$0.28 - $0.19	$8.9 M
	2012	$509.0 K	$324.5 K	$0.00	$696.0 K	$0.00	$231.5 K	$1.7 M
	2011	$390 K	$195.0 K	$123.9 K	$0.00	$0.00	$87.9 K	$796.8 K
BIORESTORATIVE (BRTX) Francisco Silva VP	2013	$230.0 K	$0.00	$0.00	$20.2 K	$0.00	$0.00	$250.2 K
	2012	$176.1 K	$0.00	$0.00	$115.2 K	$0.00	$0.00	$294.4 K
	2011	$110.7 K	$30.0 K	$0.00	$41.6 K	$0.00	$0.00	$182.3 K
BIORESTORATIVE (BRTX) Mandy Clyde Pres. Ops.	2013	$118.0 K	$0.00	$0.00	$16.18 K	$0.00	$0.00	$134.2 K
BIORESTORATIVE (BRTX) Mandy Clyde Pres. Ops.	2012	$100.0 K	$0.00	$0.00	$49.9 K	$0.00	$0.00	$149.9 K
BIOTIME (BTX) Michael West CEO	2013	$680.3 K	$65.0 K	$0.00	$851.6 K	$0.00	$37.8 K	$1.6 M	$2.21 - $4.82	$142.9 M
	2012	$660.5 K	$110.0 K	$0.00	$0.00	$0.00	$24.5 K	$785.0 K
	2011	$560.5 K	$266.0 K	$0.00	$10.6 K	$0.00	$19.0 K	$856.2 K
BIOTIME (BTX) Robert Peabody SVP	2013	$405.1 K	$145.0 K	$0.00	$521.5 K	$0.00	$12.0 K	$1.0 M
	2012	$386.9 K	$45 K	$0.00	$0.00	$0.00	$12.5 K	$444.4 K
	2011	$336.9 K	$156.0 K	$0.00	$5.3 K	$0.00	$12.4 K	$510.6 K
BIOTIME (BTX) Peter Garcia CFO	2013	$154.7 K	$0.00	$0.00	$520.8 K	$0.00	$12.8 K	$688.2 K
	2012	$324.0 K	$100.0 K	$0.00	$0.00	$0.00	$12.5 K	$436.5 K
	2011	$81.0 K	$6.0 K	$0.00	$703.2 K	$0.00	$3.4 K	$793.6 K
BIOTIME (BTX) Leslie Stoltz EVP	2013	$104.2 K	$0.00	$0.00	$591.3 K	$0.00	$0.00	$695.5 K
BIOTIME (BTX) William Tew CCO	2013	$285.0 K	$30.0 K	$0.00	$348.3 K	$0.00	$12.8 K	$671.0 K
	2012	$237.5 K	$20.0 K	$0.00	$0.00	$0.00	$11.1 K	$268.6 K
	2011	$145.0 K	$26.0 K	$0.00	$177.0 K	$0.00	$7.3 K	$355.3 K
BLUEBIRD (BLUE) Nick Leschly CEO	2013	$392.5 K	$0.00	$0.00	$1.8 M	$234.0 K	$0.00	$2.5 M	$17.03 - $36.25	$659.4 M
BLUEBIRD (BLUE) Nick Leschly CEO	2012	$346.0 K	$0.00	$0.00	$130.7 K	$124.2 K	$0.00	$601.0 K
BLUEBIRD (BLUE) Jeffrey Walsh COO	2013	$321.7 K	$0.00	$0.00	$395.8 K	$147.8 K	$0.00	$865.3 K
BLUEBIRD (BLUE) Jeffrey Walsh COO	2012	$300.7 K	$0.00	$0.00	$0.00	$108.0 K	$0.00	$408.7 K
BLUEBIRD (BLUE) Michael Finer CSO	2013	$307.2 K	$0.00		$640.2 K	$126.4 K	$0.00	$1.1 M
BRAINSTORM (BCLI) Alon Natonson Former CEO	2013	$117.0 K	$0.00	$0.00	$0.00	$0.00	$94.0 K	$211.0 K	$0.10 - $0.37	$44.8 M
BRAINSTORM (BCLI) Adrian Harel DIR RES/FMR CEO	2013	$130.0 K	$11.0 K	$0.00	$0.00	$0.00	$70.0 K	$211.0 K
	2012	$121.4 K	$60.0 K	$0.00	$16.0 K	$0.00	$71.2 K	$268.7 K
	2011	$117.0 K	$0.00	$0.00	$203.0 K	$0.00	$65.0 K	$385.0 K
BRAINSTORM (BCLI) Liat Sossover CFO	2013	$106.0 K	$0.00	$0.00	$16.0 K	$0.00	$65.0 K	$187.0 K
	2012	$99.3 K	$20.0 K	$0.00	$13.7 K	$0.00	$56.0 K	$189.0 K
	2011	$98.0 K	$0.00	$0.00	$0.00	$0.00	$46.0 K	$144.0 K
CAPRICOR (CAPR) Linda Marbán CEO	2013	$232.4 K	$0.00	$0.00	$108.0 K	$0.00	$0.00	$340.3 K	$1.50 - $17.15	$63.1 M
CAPRICOR (CAPR) Linda Marbán CEO	2012	$190.3 K	$0.00	$0.00	$0.00	$0.00	$0.00	$190.3 K
CAPRICOR (CAPR) Karen Krasney EVP/Counsel	2013	$189.4 K	$0.00	$0.00	$0.00	$0.00	$1.0 K	$190.4 K
CAPRICOR (CAPR) Karen Krasney EVP/Counsel	2012	$130.0 K	$0.00	$0.00	$54.7 K	$0.00	$1.0 K	$185.7 K
CAPRICOR (CAPR) Anthony Davies CTO	2013	$213.1 K	$0.00	$0.00	$49.3 K	$0.00	$40.6 K	$302.9 K
CAPRICOR (CAPR) Darlene Horton Former CEO	2013	$1.0 K	$239.3 K	$0.00	$0.00	$0.00	$0.00	$240.3 K
CAPRICOR (CAPR) Darlene Horton Former CEO	2012	$81.4 K	$0.00	$0.00	$0.00	$0.00	$0.00	$81.4 K
CESCA (KOOL) (THERMOGENESIS) Matthew Plavan CEO	2013	$315.0 K	$0.00	$0.00	$88.0 K	$0.00	$8.0 K	$403.0 K	$0.71 -$3.24	$45.0 M
	2012	$315.0 K	$0.00	$149.0 K	$0.00	$0.00	$0.00	$464.0 K
	2011	$301.0 K	$89.0 K	$68.0 K	$92.0 K	$0.00	$0.00	$550.0 K
CESCA (KOOL) (THERMOGENESIS) Hal Baker VP/OPS	2013	$263.0 K	$99.0 K	$0.00	$0.00	$0.00	$8.0 K	$370.0 K
	2012	$262.0 K	$85.0 K	$99.0 K	$0.00	$0.00	$9.0 K	$455.0 K
	2011	$250.0 K	$178.0 K	$0.00	$69.0 K	$0.00	$8.0 K	$505.0 K
CESCA (KOOL) (THERMOGENESIS) Kevin Cooksy VP/DEV	2013	$240.0 K	$0.00	$0.00	$0.00	$0.00	$0.00	$240.0 K
CESCA (KOOL) (THERMOGENESIS) Kevin Cooksy VP/DEV	2012	$193.0 K	$4.0 K	$82.0 K	$0.00	$0.00	$0.00	$279.0 K
CESCA (KOOL) (THERMOGENESIS) Ken Pappa VP/MANUF	2013	$245.0 K	$25.0 K	$0.00	$0.00	$0.00	$0.00	$270.0 K
	2012	$239.0 K	$0.00	$99.0 K	$0.00	$0.00	$0.00	$338.0 K
	2011	$215.0 K	$0.00	$0.00	$35.0 K	$0.00	$0.00	$250.0 K
CYTORI (CYTX) Christopher Calhoun Former CEO	2013	$467.9 K	$0.00	$635.3 K	$0.00	$82.5 K	$0.00	$1.2 M	$2.00 - $3.93	$172.8 M
	2012	$467.9 M	$0.00	$293.2 K	$483.9 K	$109.9 K	$0.00	$1.3 M
	2011	$456.5 K	$0.00	$292.4 K	$252.80	$140.30	$10.2 K	$1.1 M
CYTORI (CYTX) Marc Hendrick CEO	2013	$406.6 K	$0.00	$0.00	$465.9 K	$89.1 K	$0.00	$961.6 K
	2012	$406.6 K	$0.00	$212.7 K	$241.9 K	$76.4 K	$0.00	$937.8 K
	2011	$396.7 K	$0.00	$214.4 K	$185.4 K	$97.5 K	$0.00	$894.2 K
CYTORI (CYTX) Mark Saad CFO	2013	$389.9 K	$0.00	$0.00	$381.1 K	$35.6 K	$0.00	$806.7 K
	2012	$389.9 K	$0.00	$184.0 K	$84.1 K	$64.1 K	$0.00	$722.2 K
	2011	$380.4 K	$0.00	$194.9 K	$160.1 K	$81.8 K	$0.00	$825.8 K
	2010	$366.4 K	$0.00	$0.00	$407.3 K	$109.9 K	$0.00	$883.7 K
CYTORI (CYTX) Steven Kesten Pres. & CEO	2013	$333.3 K	$0.00	$0.00	$271.1 K	$38.9 K	$143.4 K	$786.8 K
CYTORI (CYTX) Clyde Shores EVP	2013	$329.4 K	$0.00	$0.00	$254.1 K	$25.2 K	$35.0 K	$641.8 K
CYTORI (CYTX) Clyde Shors	2012	$329.4 K	$0.00	$178.2 K	$84.1 K	$65.2 K	$44.4 K	$701.5 K
DENDREON (DNDN) John Johnson CEO	2013	$800.0 K	$0.00	$4.3 M	$0.00	$456.0 K	$7.7 K	$5.6 M	$1.81-$5.38	$369.2 M
DENDREON (DNDN) John Johnson CEO	2012	$736.4 K	$0.00	$4.7 M	$4.7 M	$912.0 K	$825.00	$11.2 M
DENDREON (DNDN) Gregory Schiffman CFO	2013	$450.0 K	$0.00	$1.1 M	$0.00	$128.3 K	907.0 K	$2.6 M
	2012	$437.0 K	$0.00	$1.1 M	NA	$118.0 K	$8.0 K	$1.6 M
	2011	$437.0 K	$0.00	$750.0 K	NA	$109.2 K	$6.9 K	$1.3 M
DENDREON (DNDN) Gregory Cox INTERIM CFO	2013	$354.1 K	$524.8 K	$0.00	$0.00	$128.3 K	$6.3 K	$1.0 M
DENDREON (DNDN) Mark Frohlich CMO	2013	$464.0 K	$1.09 M	$0.00	$0.00	$128.3 K	$906.6 K	$2.6 M
	2012	$450.0 K	$0.00	$2.4 K	$0.00	$122.0 K	$7.2 K	$3.0 M
	2011	$446.6 K	$0.00	$750.0 K	$0.00	$112.5 K	$7.3 K	$1.3 M
	2010	$360.0 K	$0.00	$642.6 K	$878.7 K	$171.7 K	$7.7 K	$2.0 M
DENDREON (DNDN) Christine Mikail COUNSEL	2013	$412.0 K	$0.00	$1.1 M	$0.00	$117.4 K	$6.2 K	$1.6 M
DENDREON (DNDN) Christine Mikail COUNSEL	2012	$334.8 K	$0.00	$650.6 K	$885.3 K	$475.5 K	$5.0 K	$2.3 M
DENDREON (DNDN) Joseph Depinto EVP/OPS	2013	$402.0 K	$0.00	$1.09 M	$0.00	$114.6 K	$9.6 K	$1.6 M
	2011	$400.0 K	$0.00	$750.0 K	$0.00	$100.0 K	$120.6 K	$1.3 M
	2010	$246.8 K	$0.00	$1.8 K	$2.5 M	$170.0 K	$128.8 K	$4.9 M
DENDREON (DNDN) John Maslowski VP OPS.	2012	$188.0 K	$0.00	$0.00	$0.00	$0.00	$0.00	$188.0 K
DENDREON (DNDN) John Maslowski VP OPS.	2011	$164.9 K	$20.0 K	$0.00	$137.2 K	$0.00	$0.00	$322.1 K
DENDREON (DNDN) Elizabeth Browning EVP MKT.	2012	$250.0 K	$0.00	$0.00	$0.00	$0.00	$0.00	$250.0 K
FATE THERAPEUTICS (FATE) Christian Weyer CEO	2013	$350.0 K	$0.00	$0.00	$0.00	$153.1 K	$0.00	$503.1 K	$4.30 - $13.55	$135.1 M
FATE THERAPEUTICS (FATE) Christian Weyer CEO	2012	$74.0 K	$0.00	$0.00	$677.5 K	$0.00	$0.00	$751.5 K
FATE THERAPEUTICS (FATE) J. Scott Wolchko CFO/COO	2013	$256.0 K	$0.00	$0.00	$145.2 K	$64.5 K	$0.00	$465.7 K
FATE THERAPEUTICS (FATE) J. Scott Wolchko CFO/COO	2012	$241.0 K	$0.00	$0.00	$96.1 K	$0.00	$0.00	$337.1 K
FATE THERAPEUTICS (FATE) Pratik Multani CMO	2013	318.00	$0.00	$0.00	$145.2 K	$66.8 K	$0.00	$530.0 K
FATE THERAPEUTICS (FATE) Pratik Multani CMO	2012	$313.0 K	$0.00	$102.3 K	$0.00	$0.00	$0.00	$415.3 K
HARVARD APPARATUS (HART) David Green CEO	2013	$84.1 K	$0.00	$0.00	$2.2 M	$0.00	$4.3 K	$2.3 M	$2.00 - $11.89	$54.8 M
HARVARD APPARATUS (HART) Thomas McNaughton CFO	2013	$51.5 K	$0.00	$0.00	$560.0 K	$0.00	$2.1 K	$613.7 K
IMMUNOCELLULAR (IMUC) Andrew Gegnos Pres. CEO	2012	$33.3 K	$0.00	$0.00	$791.4 K	$0.00	$0.00	$824.7 K	$0.65 - $4.00	$80.7 M
IMMUNOCELLULAR (IMUC) Andrew Gegnos Pres. CEO	2011	NA	$0.00	$0.00	$0.00	$0.00	$0.00	NA
IMMUNOCELLULAR (IMUC) John Yu Pres. CEO	2012	$67.7 K	$40.0 K	$0.00	$70.5 K	$0.00	$108.9 K	$287.1 K
IMMUNOCELLULAR (IMUC) Manish Singh Pres. CEO	2012	$202.7 K	$0.00	$0.00	$0.00	$0.00	$0.00	$202.7 K
IMMUNOCELLULAR (IMUC) Manish Singh Pres. CEO	2011	$313.1 K	$50.0 K	$0.00	$393.5 K	$0.00	$0.00	$756.6 K
IMMUNOCELLULAR (IMUC) David Factor CFO	2012	$116.4 K	$20.0 K	$0.00	$10.3 K	$0.00	$0.00	$146.7 K
IMMUNOCELLULAR (IMUC) David Factor CFO	2011	$62.0 K	$0.00	$0.00	$52.1 K	$0.00	$0.00	$114.1 K
IMMUNOCELLULAR (IMUC) James Bender VP/Prod. Dev.	2012	$186.9 K	$34.1 K	$0.00	$145.4 K	$0.00	$0.00	$366.4 K
IMMUNOCELLULAR (IMUC) James Bender VP/Prod. Dev.	2011	$174.5 K	$20.0 K	$0.00	$134.8 K	$0.00	$0.00	$329.3 K
INT'L STEM (ISCO) Andrew Semechkin Chair/CEO	2013	$258.5 K	$0.00	$0.00	$23.0 K	$0.00	$0.00	$281.5 K	$0.13 - $0.30	$23.8 M
	2012	$255.0 K	$0.00	$0.00	$176.8 K	$0.00	$0.00	$431.8 K
	2011	$255.3 K	$0.00	$0.00	$2.8 M	$0.00	$0.00	$3.0 M
INT'L STEM (ISCO) John Craw	2013	$220.0 K	$0.00	$0.00	$17.3 K	$0.00	$0.00	$237.3 K
INT'L STEM (ISCO) John Craw	2012	$215.7 K	$0.00	$0.00	$51.6 K	$0.00	$0.00	$267.4 K
INT'L STEM (ISCO) Ruslan Semechkin CSO	2013	$182.0 K	$0.00	$0.00	$16.1 K	$0.00	$0.00	$198.2 K
	2012	$176.5 K	$0.00	$0.00	$59.3 K	$0.00	$0.00	$235.8 K
	2011	$176.5 K	$0.00	$0.00	$581.6 K	$0.00	$0.00	$758.2 K
MESOBLAST (MBLTY) NA (AUSTRALIA) NO FINANCIALS W/SEC SOURCE: BLOOMBERG Silviu Itescu CEO	2013	1.7 AUD							$21.39 - $31.60	$1.39 B
MIMEDX (MDXG) Parker Petit CEO	2013	$456.2 K	$0.00	$548.3 K	$954.0 K	$292.5 K	$0.00	$2.3 M	$1.81 - $8.80	$569.8 M
	2012	$354.3 K	$0.00	$0.00	$706.7 K	$0.00	$0.00	$1.0 M
	2011	$325.0 K	$0.00	$0.00	$696.5 K	$0.00	$0.00	$1.0 M
MIMEDX (MDXG) William Taylor COO	2013	$385.6 K	$0.00	$377.6 K	$649.0 K	$240.7 K	$0.00	$1.7 M
	2012	$343.8 K	$0.00	$0.00	$530.0 K	$0.00	$0.00	$873.8 K
	2011	$300.0 K	$0.00	$0.00	$352.8 K	$0.00	$0.00	$652.8 K
MIMEDX (MDXG) Roberta McCraw Counsel	2013	$240.0 K	$0.00	$71.0 K	$156.4 K	$106.3 K	$0.00	$573.8 K
MIMEDX (MDXG) Michael Senken CFO	2013	$268.3 K	$0.00	$172.0 K	$278.0 K	$121.9 K	$0.00	$840.3 K
	2012	$236.5 K	$0.00	$0.00	$160.2 K	$0.00	$0.00	$396.7 K
	2011	$198.2 K	$0.00	$0.00	$213.9 K	$0.00	$0.00	$412.2 K
NEOSTEM (NBS) Robin Smith CEO	2013	$495.0 K	$450.0 K	$0.00	$249.7 K	$0.00	$40.8 K	$1.2 M	$4.56 - $9.89	$173.6 M
	2012	$412.6 K	$363.0 K	$183.8 K	$638.9 K	$0.00	$44.9 K	$1.6 M
	2011	$375.1 K	$330.0 K	$0.00	$2.9 M	$0.00	$30.4 K	$3.6 M
NEOSTEM (NBS) Robert Preti CSO	2013	$349.2 K	$145.0 K	$0.00	$143.2 K	$0.00	$0.00	$637.5 M
	2012	$309.8 K	$0.00	$0.00	$97.5 K	$0.00	$0.00	$407.4 K
	2011	$300.8 K	$0.00	$0.00	$439.0 K	$0.00	$6.3 K	$746.1 K
NEOSTEM (NBS) Andrew Pecora CVO	2013	$221.5 M	$365.0 M	$0.00	$286.5 K	$0.00	$0.00	$873.0 M
	2012	$183.0 M	$0.00	$0.00	$61.7 K	$0.00	$0.00	$244.9 K
	2011	$174.2 K	$0.00	$0.00	$688.7 K	$0.00	$0.00	$863.0 K
NEOSTEM (NBS) Douglas Lesordo CMO	2013	$291.5 K
NEURALSTEM (CUR) I. Richard Garr CEO	2013	$407.0 K	$244.2 K	$0.00	$407.0 K	$0.00	$6.0 K	$1.06 M	$1.30 - $4.80	$317.6 M
	2012	407.00	$195.3 K	$0.00	$407.0 K	$0.00	$6.0 K	$1.0 M
	2011	$407.0 K	$73.2 K	$0.00	$512.8 K	$0.00	$6.0 K	$999.0 K
NEURALSTEM (CUR) Karl Johe CSO	2013	$422.1 K	$253.2 K	$0.00	$2.3 M	$0.00	$6.0 K	$3.0 M
	2012	$422.1 K	$253.2 K	$0.00	$1.8 M	$0.00	$6.0 K	$2.5 M
	2011	$422.1 K	$253.2 K	$0.00	$422.1 K	$0.00	$6.0 K	$1.1 M
NORTHWEST BIO (NWBO) Linda Powers CEO	2013	$360.0 K	$0.00	$0.00	$0.00	$0.00	$0.00	$360.0 K	$3.10 - $3.64	$330.5 M
	2012	$360.0 K	$0.00	$0.00	$0.00	$0.00	$0.00	$360.0 K
	2011	$203.3 K	$0.00	$0.00	$9.2 M	$0.00	$0.00	$9.4 M
NORTHWEST BIO (NWBO) Alton Boyton CSO	2013	295.60	$0.00	$0.00	$0.00	$0.00	$0.00	$295.60
	2012	$295.0 K	$0.00	$0.00	$0.00	$0.00	$0.00	$295.0 K
	2011	$334.7 K	$0.00	$0.00	$1.5 M	$0.00	$0.00	$1.8 M
NORTHWEST BIO (NWBO) Anthony Maida COO	2013	$300.0 K	$0.00	$0.00	$0.00	$0.00	$0.00	$300.0 K
	2012	$300.0 K	$0.00	$0.00	$0.00	$0.00	$0.00	$300.0 K
	2011	$160.3 K	$0.00	$0.00	$814.1 K	$0.00	$0.00	$974.5 K
NORTHWEST BIO (NWBO) Leslie Goldman Sr. VP	2013	$348.0 K	$0.00	$0.00	$0.00	$0.00	$0.00	$348.0 K
	2012	$348.0 K	$0.00	$0.00	$0.00	$0.00	$0.00	$348.0 K
	2011	$149.0 K	$0.00	$0.00	$1.4 M	$0.00	$0.00	$1.6 M
NORTHWEST BIO (NWBO) Marnix Bosch CTO	2013	325.20	$0.00	$0.00	$0.00	$0.00	$0.00	$325.20
	2012	$325.0 K	$0.00	$0.00	$0.00	$0.00	$0.00	$325.0 K
	2011	$339.3 K	$20.0 K	$0.00	$1.1 M	$0.00	$0.00	$1.5 M
ORGANOVO (ONVO) Keith Murphy CEO	2012	$298.8 K	$0.00	$680.0 K	$0.00	$90.6 K	$0.00	$1.0 M	$3.64 - $13.65	$523.3 M
	2011	$217.7 K	$30.0 K	$0.00	$0.00	$0.00	$0.00	$247.7 K
	2010	$110.0 K	$0.00	$0.00	$0.00	$0.00	$0.00	$110.0 K
ORGANOVO (ONVO) Barry Michaels CFO	2012	$241.8 K	$0.00	$1.2 M	$234.4 K	$73.9 K	$0.00	$1.8 M
ORGANOVO (ONVO) Barry Michaels CFO	2011	$74.3 K	$25.0 K	$0.00	$0.00	$0.00	$0.00	$99.3 K
ORGANOVO (ONVO) Sharon Presnell EVP/R&D	2012	$253.2 K	$0.00	$0.00	$303.9 K	$77.5 K	$0.00	$634.8 K
ORGANOVO (ONVO) Sharon Presnell EVP/R&D	2011	$157.3 K	$50.0 K	$0.00	$54.6 K	$0.00	$24.6 K	$286.7 K
ORGANOVO (ONVO) Eric David C. Strat Off.	2012	$160.9 K	$22.5 K	$0.00	$757.7 K	$47.4 K	$28.2 K	$1.0 M
ORGANOVO (ONVO) Michael Renard EVP/OPS.	2012	$159.9 K	$0.00	$0.00	$758.9 K	$46.2 K	$40.0 K	$1.0 M
OPEXA (OPXA) Neil Warma CEO	2013	$396.5 K	$0.00	$53.7 K	$92.3 K	$0.00	$0.00	$542.6 K	$1.25 - $3.70	$39.5 M
	2012	$396.5 K	$50.0 K	$0.00	$688.6 K	$0.00	$0.00	$1.1 M
	2011	$385.0 K	$50.0 K	$0.00	$115.0 K	$0.00	$0.00	$550.0 K
OPEXA (OPXA) Donna Rill SVP/OPS	2013	$240.0 K	$22.0 K	$37.8 K	$34.3 K	$0.00	$0.00	$334.0 K
	2012	$220.0 K	$15.0 K	$0.00	$154.1 K	$0.00	$0.00	$389.4 K
	2011	$200.0 K	$15.0 K	$0.00	$38.3 K	$0.00	$0.00	$253.3 K
OPEXA (OPXA) Karthik Radhakrishnan CDO	2013	$220.0 K	$10.0 K	$0.00	$154.1 K	$0.00	$0.00	$384.2 K
OPEXA (OPXA) Karthik Radhakrishnan CDO	2011	$200.0 K	$15.0 K	$0.00	$38.3 K	$0.00	$0.00	$253.3 K
OSIRIS (OSIR) C. Randall Mills FORMER CEO	2013	`$434.8 K	$0.00	$0.00	$120.0 K	$0.00	$0.00	$554.8 K	$10.00 - $27.40	$535.6 M
	2012	$470.0 K	$120.0 K	$0.00	$0.00	$0.00	$0.00	$590.0 K
	2011	$470.0 K	$120.0 K	$0.00	$146.6 K	$0.00	$0.00	$736.4 K
OSIRIS (OSIR) Philip Jacoby Jr. CFO	2013	$207.3 K	$20.0 K	$0.00	$80.0 K	$0.00	$0.00	$419.0 K
	2012	$193.0 K	$18.0 K	$0.00	$52.0 K	$0.00	$0.00	$263.0 K
	2011	$189.1 K	$18.0 K	$0.00	$73.2 K	$0.00	$0.00	$280.3 K
OSIRIS (OSIR) Lode Debrabandere COO	2013	$316.7 K	$50.0 K	$0.00	$120.0 K	$0.00	$20.0 K	$507.0 K
	2012	$292.2 K	$35.0 K	$0.00	$65.0 K	$0.00	$0.00	$392.2 K
	2011	$286.6 K	$35.0 K	$0.00	$91.5 K	$0.00	$0.00	$412.5 K
OSIRIS (OSIR) Michelle Williams CSO	2013	$278.8 K	$40.0 K	$0.00	$100.0 K	$0.00	$0.00	$554.8 K
	2012	$271.5 K	$35.0 K	$0.00	$65.0 K	$0.00	$0.00	$371.5 K
	2011	$266.0 K	$35.0 K	$0.00	$91.5 K	$0.00	$0.00	$392.5 K
PLURISTEM (PSTI) Zami Aberman CEO	2013	$489.9 K	$75.0 K	$1.0 M	$0.00	$0.00	$21.0 K	$1.6 M	$2.47 - $4.63	$237.7 M
	2012	$495.6 K	$0.00	$899.5 M	$0.00	$75.0 K	$21.7 K	$1.4 M
	2011	$383.0 K	$0.00	$900.9 K	$0.00	$0.00	$21.6 K	$1.3 M
PLURISTEM (PSTI) Yaky Yanay CFO	2013	$251.3 K	$75.0 K	$770.0 K	$0.00	$0.00	$27.9 K	$1.1 M
	2012	$251.7 K	$0.00	$642.5 K	$0.00	$50.1 K	$27.2 K	$973.6 K
	2011	$200.7 K	$0.00	$629.4 K	$0.00	$0.00	$31.7 K	$861.9 K
PROTEONOMIX (PROT) Michael Cohen CEO	2011	$250.0 K	$75.0 K	$0.00	$0.00	$0.00	$40.0 K	$365.0 K
PROTEONOMIX (PROT) Michael Cohen CEO	2010	$250.0 K	$75.0 K	$0.00	$0.00	$0.00	$40.0 K	$365.0 K
STEMCELLS (STEM) Martin McGlynn CEO	2013	$548.5 K	$287.4 K	$1.2 M	$0.00	$0.00	$43.30	$2.1 M	$0.03 - $0.30	$237.3 K
	2012	$550.0 K	$202.1 K	$430.3 K	$0.00	$0.00	$50.5 K	$1.2 M
	2011	$525.0 K	$187.6 K	$194.0 K	$0.00	$0.00	$48.8 K	$955.5 K
STEMCELLS (STEM) Ann Tsukamoto EVP	2013	$330.0 K	$127.3 K	$515.2 K	$0.00	$0.00	$27.0 K	$999.5 K
	2012	$335.0 K	$84.0 K	$137.8 K	$0.00	$0.00	$26.4 K	$583.2 K
	2011	$300.0 K	$78.0 K	$0.00	$0.00	$0.00	$24.4 K	$402.4 K
STEMCELLS (STEM) Stewart Craig EVP	2013	$298.5 K	$114.0 K	$512.4 K	$0.00	$0.00	$34.2 K	$959.1 K
	2012	$300.0 K	$77.0 K	$137.8 K	$0.00	$0.00	$29.8 K	$544.6 K
	2011	$275.0 K	$71.5 K	$0.00	$0.00	$0.00	$27.8 K	$374.3 K
STEMLINE (STML) Ivan Bergstein CEO	2013	$449.7 K	$321.1 K	$1.2 M	$0.00	$916.4 K	$0.00	$2.9 M	$12.10 - $27.25	$192.7 M
	2012	$350.0 K	$0.00	$0.00	$396.4 K	$0.00	$0.00	$746.4 K
	2011	$350.0 K	$0.00	$0.00	$175.8 K	$0.00	$0.00	$525.8 K
STEMLINE (STML) Eric Rowinsky EVP	2013	$341.7 K	$175.0 K	$1.9 M	$0.00	$277.5 K	$191.6 K	$2.0 M
	2012	$250.0 K	$0.00	$0.00	$918.5 K	$0.00	$0.00	$1.1 M
	2011	$41.6 K	$0.00	$0.00	$0.00	$0.00	$0.00	$41.6 K
STEMLINE (STML) Stephen Hall Former CAO	2013	$227.0 K	$0.00	$995.2 K	$0.00	$72.0 K	$0.00	$1.3 M
STEMLINE (STML) Stephen Hall Former CAO	2012	$25.0 K	$0.00	$0.00	$0.00	$0.00	$32.0 K	$57.0 K
STEMLINE (STML) David Gionco CAO	2013	0.00	$0.00	$0.00	$0.00	$0.00	$13.0 K	$13.0 K
STEMLINE (STML) Kenneth Hoberman COO	2013	$364.6 K	$187,5 K	$0.00	$0.00	$283.4 K	$0.00	$834.4 K
TENGION (TNGN) John Miclot CEO	2013	$462.3 K	$0.00	$0.00	$0.00	$209 K	$39.0 K	$709.9 K	$0.15 - $1.39	$1.2 M
	2012	$450.0 K	$0.00	$224.4 K	$159.9 K	$202.5 K	$100.6 K	$1.1 M
	2011	$34.0 K	$0.00	$0.00	$224.0 K	$0.00	$0.00	$258.1 K
TENGION (TNGN) Timothy Betram CSO	2013	$380.8 K	$0.00	$0.00	$0.00	$137.4 K	$0.00	$518.2 K
	2012	$373.4 K	$0.00	$92.2 K	$77.7 K	$133.4 K	$0.00	$626.9 K
	2011	$316.1 K	$0.00	$96.8 K	$98.4 K	$79.5 K	$1.3 K	$592.2 K
TENGION (TNGN) A. Brian Davis CFO	2013	$336.6 K	$0.00	$0.00	$0.00	$112.6 K	$26.6 K	$475.9 K
	2012	$319.4 K	$0.00	$43.8 K	$36.5 K	$100.4 K	$0.00	$554.3 K
	2011	$292.8 K	$0.00	$56.4 K	$57.0 K	$72.2 K	$0.00	$478.9 K
VISTAGEN (VSTA) Shawn Singh CEO	2013	$201.6 K	$0.00	$0.00	$802.4 K	$0.00	$0.00	$1.0 M	$0.25 - $0.89	$15.9 M
VISTAGEN (VSTA) Shawn Singh CEO	2012	$292.2 K	$0.00	$0.00	$108.5 K	$0.00	$230.1 K	$630.4 K
VISTAGEN (VSTA) H. Ralph Snodgrass CSO	2013	$203.0 K	$0.00	$0.00	$534.9 K	$0.00	$0.00	$738.0 K
VISTAGEN (VSTA) H. Ralph Snodgrass CSO	2012	$249.4 K	$0.00	$0.00	$105.6 K	$0.00	$100.0 K	$455.0 K
VISTAGEN (VSTA) Jerold Dotson CFO	2013	$97.2 K	$0.00	$0.00	$134.3 K	$0.00	$62.3 K	$293.9 K
VISTAGEN (VSTA) Jerold Dotson CFO	2012	0.00	$0.00	$0.00	$108.5 K	$0.00	$71.2 K	$179.8 K
VERASTEM (VSTM) Robert Forrester CEO	2013	$443.8 K	$0.00	$0.00	$2.1 M	$248.0 K	$15.5 K	$2.8 M	$7.10 - $18.82	$207.2 M
	2012	$364.4 K	$0.00	$1.5 M	$0.00	$190.0 K	$14.0 K	$2.1 M
	2011	$252.7 K	$0.00	$35.8 K	$0.00	$130.0 K	$7.0 K	$425.6 K
VERASTEM (VSTM) Daniel Paterson VP/DEV	2013	$314.7 K	$0.00	$0.00	$513.0 K	$150.4 K	$12.5 K	$990.6 K
VERASTEM (VSTM) Daniel Paterson VP/DEV	2012	$244.6 K	$0.00	$1.26 M	$0.00	$116.0 K	$10.2 K	$1.6 M
VERASTEM (VSTM) Joanna Horobin CMO	2013	$350.0 K	$0.00	$0.00	$0.00	$169.0 K	$13.6 K	$532.6 K
VERASTEM (VSTM) Joanna Horobin CMO	2012	$59.2 K	$0.00	$0.00	$1.3 M	$20.0 K	$322.00	$1.33 M

Search form

Subscribe for Full Access

Subscribe for Full Access

Top Sections:

Sell

Hold

Buy

Sell

Buy

Hold

Hold

Buy

Hold

Sell

Hold

Hold

Hold

Sell

Sell

Buy

Hold

Sell

Sell

Buy

Buy

Buy

Buy

Hold

Buy

Sell

Buy

Sell

Hold

Hold

Scoreboard

The Scorecard is a performance management tool which can be used by investors to keep track of the execution of activities and to monitor the consequences arising from these actions.

“Cash is king" is an acute expression used in analyzing the RegMed universe to the importance of operating funds available in the development and trial process and the overall fiscal health of a business.

An earnings release is a ‘scorecard’ of sorts for a public regenerative medicine company.

An earnings release is a ‘scorecard’ of sorts for a public regenerative medicine company.

Coverage Ticker